Chris Rhem

Cooley advised Alarm.com Holdings, a platform for the intelligently connected property, on its $500 million convertible note offering.

Cooley advised Sazerac, one of the world’s largest distilled spirits companies, on its agreement to acquire BuzzBallz, a woman-owned and family-operated distillery, winery and brewery in Texas.

Cooley advised Blue Owl Capital, a top asset manager redefining alternatives, on its strategic investment a $300 million royalty financing and a $450 million credit facility in BridgeBio Pharma, a commercial-stage biopharmaceutical company focused on genetic diseases and cancers.

Cooley advised MannKind, a company focusing on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases, on the sale of a 1% royalty in net sales of Tyvaso DPI (treprostinil) inhalation powder to Sagard Healthcare for up to $200 million.

Cooley advised Blue Owl Capital, a top asset manager that is redefining alternatives, on its strategic investment – consisting of a nondilutive, nonrecourse royalty-backed loan of up to $140 million – in XOMA Corporation, a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health.